Kidney Transplant Recipients Benefit from SARS-CoV-2 Vaccination

In an observational study in the Czech Republic, two doses of SARS-CoV-2 mRNA vaccine reduced adjusted risk for infection by about half.

Although immunosuppressed patients (who have diminished responses to most vaccines) were not included in the initial placebo-controlled trials of COVID-19 vaccines, reduced serologic responses to SARS-CoV-2 vaccination have been demonstrated among solid organ transplant recipients (e.g., NEJM JW Infect Dis May 2021 and JAMA 2021 Mar 15; [e-pub]). However, information about clinical protection for these patients is lacking. In a retrospective, observational study, researchers in the Czech Republic used national registry data to report on COVID-19 infections in kidney transplant recipients (KTRs) during the initial vaccine roll-out in early 2021.

Among 2101 KTRs, COVID-19 developed in 33 vaccinated (2 doses of mRNA vaccine) and 79 unvaccinated…

Reviewing Author

Daniel Kaul, MD

Disclosures

Grant/Research SupportNobelpharma; Pfizer

Leadership Positions in Professional SocietiesAmerican Society of Transplantation (Program Committee)

Daniel Kaul, MD

Disclosures

Grant/Research SupportNobelpharma; Pfizer

Leadership Positions in Professional SocietiesAmerican Society of Transplantation (Program Committee)

Kidney Transplant Recipients Benefit from SARS-CoV-2 Vaccination

Topics

Reviewing Author